Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Aurora Cannabis Inc. (ACB) vs Emergent Biosolutions Inc. (EBS)

Aurora Cannabis Inc. and Emergent Biosolutions Inc. are both Drug Manufacturers Specialty & Generic companies. Emergent Biosolutions Inc. is the larger, with a market value of $347.1M against $267.8M — 1.3× the size. Emergent Biosolutions Inc. grew revenue faster over the last twelve months: −9.56% against −18.2%. Emergent Biosolutions Inc. has the higher net margin (−23.0% vs −38.1%) and the higher return on invested capital (−5.27% vs −5.58%). Across the 19 metrics below, Emergent Biosolutions Inc. leads on 12 and Aurora Cannabis Inc. on 7.

Valuation

Metric ACB EBS Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 1.20 0.45 2.25
P/B 0.66 1.03 1.90
Price to free cash flow n/m 4.07 16.54
EV/EBITDA n/m 21.47 12.29
EV/Sales 0.96 1.03 2.56
Earnings yield (34.39%) (50.66%) (2.99%)
Free cash flow yield (14.28%) 24.57% 0.00%

Profitability

Metric ACB EBS Drug Manufacturers Specialty & Generic median
Gross margin 49.74% 55.87% 53.94%
Operating margin (12.13%) (8.57%) 0.00%
Net margin (38.12%) (22.96%) 0.00%
Free cash flow margin (17.19%) 11.18% 0.00%
Return on equity (19.85%) (40.29%) (0.40%)
Return on assets (15.19%) (13.95%) (3.32%)
Return on invested capital (5.58%) (5.27%) 0.00%

Growth

Metric ACB EBS Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (18.18%) (9.56%) 10.01%
EPS growth (last fiscal year) (5,266.67%) 125.83% —
Revenue growth, 5-year CAGR 3.92% (13.74%) 6.74%
Net income growth, 5-year CAGR 0.00% (29.64%) 0.00%

Health

Metric ACB EBS Drug Manufacturers Specialty & Generic median
Debt to equity 0.03 1.70 0.05
Current ratio 5.36 5.42 2.31
Net debt to EBITDA 5.11 1.76 0.85

Dividend

Metric ACB EBS Drug Manufacturers Specialty & Generic median
Dividend yield — 0.79% 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric ACB EBS Drug Manufacturers Specialty & Generic median
Market cap 267.79m 347.12m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack